| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
27,210,000 |
| Market
Cap: |
20.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5995 - $6.23 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Biora Therapeutics is a biotechnology company developing oral biotherapeutics. Co. is also developing diagnostics devices to help characterize the gastrointestinal (GI) tract and diagnose GI diseases like Small Intestine Bacterial Overgrowth through the development of technologies that are designed to diagnose at the site of the disease. Co.'s Targeted Therapeutics program includes PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis. Co.'s Systemic Therapeutics program includes PGN-OB1, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System for the treatment of inflammatory conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
12,506,250 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
7,517 |
| Total Sell Value |
$0 |
$0 |
$0 |
$4,585 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cooper Matthew T |
Chief Scientific Officer |
• – – |
2021-02-15 |
4 |
D |
$5.60 |
$3,707 |
D/D |
(662) |
50,961 |
|
- |
|
| Shihabi Sami |
Chief Commercial Officer |
• – – |
2021-02-15 |
4 |
D |
$5.60 |
$5,219 |
D/D |
(932) |
37,685 |
|
- |
|
| Gianakopoulos George |
Senior Vice President of Sales |
• – – |
2021-02-15 |
4 |
D |
$5.60 |
$2,111 |
D/D |
(377) |
22,279 |
|
- |
|
| Desparbes Eric |
Chief Financial Officer |
• – – |
2020-12-19 |
4 |
D |
$6.32 |
$7,761 |
D/D |
(1,228) |
99,392 |
|
- |
|
| Gianakopoulos George |
Senior Vice President of Sales |
• – – |
2020-12-19 |
4 |
D |
$6.32 |
$5,328 |
D/D |
(843) |
22,656 |
|
- |
|
| Cooper Matthew T |
Chief Scientific Officer |
• – – |
2020-12-19 |
4 |
D |
$6.32 |
$11,408 |
D/D |
(1,805) |
51,623 |
|
- |
|
| Stylli Harry |
Chairman & CEO |
• • • |
2020-12-19 |
4 |
D |
$6.32 |
$54,447 |
D/D |
(8,615) |
14,608,259 |
|
- |
|
| Neumann Clarke |
General Counsel and Secretary |
• – – |
2020-12-19 |
4 |
D |
$6.32 |
$10,908 |
D/D |
(1,726) |
52,962 |
|
- |
|
| Shihabi Sami |
Chief Commercial Officer |
• – – |
2020-12-19 |
4 |
D |
$6.32 |
$11,104 |
D/D |
(1,757) |
38,617 |
|
- |
|
| Silvestry Damon |
Chief Operating Officer |
• – – |
2020-12-16 |
4 |
B |
$4.40 |
$265,857 |
D/D |
58,081 |
221,230 |
2.74 |
- |
|
| Silvestry Damon |
Chief Operating Officer |
• – – |
2020-12-15 |
4 |
B |
$4.07 |
$259,951 |
D/D |
63,870 |
163,149 |
2.74 |
- |
|
| Alter Jeffrey D. |
Director |
– • – |
2020-12-14 |
4 |
B |
$4.85 |
$97,000 |
D/D |
20,000 |
38,335 |
2.39 |
- |
|
| Athyrium Opportunities Associates Lp |
10% Owner |
– – • |
2020-12-07 |
4 |
B |
$3.27 |
$13,499,999 |
I/I |
4,128,440 |
26,991,626 |
1.5 |
- |
|
| Nb Alternatives Gp Holdings Llc |
10% Owner |
– – • |
2020-12-07 |
4 |
B |
$3.27 |
$13,499,999 |
I/I |
4,128,440 |
26,991,626 |
1.5 |
- |
|
| Silvestry Damon |
Chief Operating Officer |
• – – |
2020-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
99,279 |
|
- |
|
| Seelye Troy |
Chief Information Officer |
• – – |
2020-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
14,493 |
36,749 |
|
- |
|
| Cooper Matthew T |
Chief Scientific Officer |
• – – |
2020-09-03 |
4 |
B |
$8.55 |
$78,241 |
D/D |
9,151 |
53,428 |
2.74 |
- |
|
| Cooper Matthew T |
Chief Scientific Officer |
• – – |
2020-09-02 |
4 |
B |
$8.55 |
$846 |
D/D |
99 |
44,277 |
2.66 |
- |
|
| Stylli Harry |
Chairman & CEO |
• • • |
2020-08-19 |
4 |
B |
$8.94 |
$89,400 |
D/D |
10,000 |
14,463,969 |
3.23 |
- |
|
| Desparbes Eric |
Chief Financial Officer |
• – – |
2020-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
36,243 |
100,620 |
|
- |
|
| Neumann Clarke |
General Counsel and Secretary |
• – – |
2020-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,534 |
54,688 |
|
- |
|
| Athyrium Opportunities Associates Lp |
10% Owner |
– – • |
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
19,569,853 |
23,303,346 |
|
- |
|
| Athyrium Opportunities Associates Lp |
10% Owner |
– – • |
2020-06-23 |
4 |
B |
$15.00 |
$49,999,995 |
I/I |
3,333,333 |
23,303,346 |
1.5 |
- |
|
| Nb Alternatives Holdings Llc |
10% Owner |
– – • |
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
19,569,853 |
23,303,346 |
|
- |
|
| Nb Alternatives Holdings Llc |
10% Owner |
– – • |
2020-06-23 |
4 |
B |
$15.00 |
$49,999,995 |
I/I |
3,333,333 |
23,303,346 |
1.5 |
- |
|
140 Records found
|
|
Page 5 of 6 |
|
|
